Sinopharm Accord disclosed its semi-annual report on August 28. In the first half of 2026, it achieved operating revenue of 36.266 billion yuan, down 1.44% year on year. Net profit attributable to shareholders of the listed company was 606 million yuan, down 8.97% year on year, with basic earnings per share of 0.99 yuan. Among this, the distribution segment achieved operating revenue of 26.539 billion yuan, down 0.91% year on year. Sinopharm Accord Grand Pharmacy achieved operating revenue of 10.227 billion yuan, down 2.40% year on year, with the decline narrowing somewhat. However, affected by industry policy adjustments, intensifying market competition and other factors, sales revenue slipped slightly, and combined with changes in the sales structure, the proportion of high-margin product sales decreased, leading to lower profit. In addition, the company's important associated enterprises were affected by international geopolitical factors, pharmaceutical industry policies, market supply and demand and other factors, and their performance declined, with corresponding investment income falling 30.43% year on year.
China National Accord Medicines Corp LtdH1 net profit fell 8.97% YoY and revenue declined 1.44% on policy adjustments and weaker high-margin sales.
Sinopharm Accord Grand Pharmacy revenue fell 2.40% YoY as sales revenue slipped amid policy and competitive pressure.
